avapro and su 11248
avapro has been researched along with su 11248 in 2 studies
Research
Studies (2)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bamias, A; Constantinidis, C; Deliveliotis, C; Dimopoulos, MA; Karadimou, A; Lainakis, G; Manios, E; Michas, F; Zakopoulos, N | 1 |
Reviews
1 review(s) available for avapro and su 11248
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Other Studies
1 other study(ies) available for avapro and su 11248
| Article | Year |
|---|---|
The use of 24-h ambulatory blood pressure monitoring (ABPM) during the first cycle of sunitinib improves the diagnostic accuracy and management of hypertension in patients with advanced renal cancer.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Antineoplastic Agents; Benzopyrans; Biphenyl Compounds; Blood Pressure Monitoring, Ambulatory; Carcinoma, Renal Cell; Ethanolamines; Female; Humans; Hydrochlorothiazide; Hypertension; Indoles; Irbesartan; Male; Middle Aged; Nebivolol; Prevalence; Pyrroles; Reproducibility of Results; Sunitinib; Tetrazoles; Time Factors; Treatment Outcome | 2011 |